You are here
Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer
Hope S. RugoClinical Breast Cancer, Vol. 16, No. 1, 18-22
Presentation by Dr. Benjamin Besse at the TAO Congress on 19/20 November 2015Dr. Benjamin Besse is Head of the Thoracic Unit at the cancer-research institute and oncology health centre Institut Gustave Roussy...
Presentation by Dr. Lysiane Marthey at the TAO Congress on 19/20 November 2015During cancer treatment, various digestive toxicities can occur. This presentation focuses on two frequent side effects of the digestive system:...
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
A. Lipton, K. Fizazi, A.T. Stopeck, D.H. Henry, M.R. Smith, N. Shore, M. Martin, S. Vadhan-Raj, J.E. Brown, G.E. Richardson, F. Saad, D.A. Yardley, K. Zhou, A. Balakumaran, A. Braun
European Journal of Cancer, Volume 53, January 2016, Pages 75-83
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial
C. Weinstein, K. Jordan, S. A. Green, E. Camacho, S. Khanani, E. Beckford-Brathwaite, W. Vallejos, L. W. Liang, S. J. Noga & B. L. RapoportAnnals of Oncology 27: 172–178, 2016
Presentation by Dr. Richard Gralla at the TAO Congress on 19/20 November 2015Despite marked progress in effective antiemetic prophylaxis, new antiemetic regimens are necessary, as many patients still experience emesis with chemotherapy,...
Role of Psychosocial Variables on Chemotherapy-Induced Nausea and Vomiting and Health-Related Quality of Life among Cancer Patients: A European Study
Grassi L, Berardi MA, Ruffilli F, et al.; IOR-IRST Psycho-Oncology and UniFE Psychiatry Co-Authors.Psychother Psychosom. 2015;84(6):339-47
Olanzapine in the Management of Difficult to Control Nausea and Vomiting in a Palliative Care Population: A Case Series
MacKintosh D.J Palliat Med. 2015 Sep 23. [Epub ahead of print]
Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy
Yosuke Ando, Takahiro Hayashi, Kaori Ito, Eri Suzuki, Naoyuki Mine, et al.Supportive Care in Cancer, 25 July 2015, 8p